Related references
Note: Only part of the references are listed.KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond
Umberto Malapelle et al.
JOURNAL OF CLINICAL PATHOLOGY (2014)
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
Alain R. Thierry et al.
NATURE MEDICINE (2014)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Comparison of COBAS 4800 KRAS, TaqMan PCR and High Resolution Melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas
Alexandre Harle et al.
VIRCHOWS ARCHIV (2013)
Validation of KRAS Testing for Anti-EGFR Therapeutic Decisions for Patients With Metastatic Colorectal Carcinoma
Suzanne Kamel-Reid et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2012)
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
Mi-Jung Kim et al.
BMC CANCER (2012)
A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens
D. Gonzalez de Castro et al.
BRITISH JOURNAL OF CANCER (2012)
Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review
Cheng-Bo Han et al.
CANCER INVESTIGATION (2012)
Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)
Pilar Garcia-Alfonso et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2012)
The utility of diagnostic biopsy specimens for predictive molecular testing in colorectal cancer
Wakkas Fadhil et al.
HISTOPATHOLOGY (2012)
Hurdles and Complexities of Codon 13 KRAS Mutations
Maria Pia Morelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Low Percentage of KRAS Mutations Revealed by Locked Nucleic Acid Polymerase Chain Reaction: Implications for Treatment of Metastatic Colorectal Cancer
Mariella Dono et al.
MOLECULAR MEDICINE (2012)
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
C. Bokemeyer et al.
ANNALS OF ONCOLOGY (2011)
KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab
H. Bando et al.
BRITISH JOURNAL OF CANCER (2011)
Impact of BRAF Mutation and Microsatellite Instability on the Pattern of Metastatic Spread and Prognosis in Metastatic Colorectal Cancer
Ben Tran et al.
CANCER (2011)
Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors
Teodora Evgenieva Goranova et al.
CLINICAL & EXPERIMENTAL METASTASIS (2011)
Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer
Francesca Molinari et al.
CLINICAL CANCER RESEARCH (2011)
KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma
N. K. B. Pang et al.
CYTOPATHOLOGY (2011)
Molecular Genetics External Quality Assessment Pilot Scheme for KRAS Analysis in Metastatic Colorectal Cancer
Zandra C. Deans et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2011)
Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase
Patricia J. T. A. Groenen et al.
HISTOPATHOLOGY (2011)
Should Oncologists Be Aware in Their Clinical Practice of KRAS Molecular Analysis?
Daniele Santini et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment
Nicola Normanno et al.
PLOS ONE (2011)
Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing
Susan D. Richman et al.
ANALYTICAL CELLULAR PATHOLOGY (2011)
Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
Stephan E. Baldus et al.
CLINICAL CANCER RESEARCH (2010)
A standardized framework for the validation and verification of clinical molecular genetic tests
Christopher J. Mattocks et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2010)
A Multicenter Blinded Study to Evaluate KRAS Mutation Testing Methodologies in the Clinical Setting
Vicki Whitehall et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The effects of tissue fixation alternatives on DNA content - A study on normal colon tissue
Gulcan Baloglu et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2008)
Effect of fixatives and tissue processing on the content and integrity of nucleic acids
M Srinivasan et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)